Leaflet PULMOZYME 2500U / 2.5ml solution for inhalation by nebuliser

Product code:
W61214001
Quantity:
6
Indicated for:
cystic fibrosis
Route of administration:
inhalation
Substance:
dornase alfa (enzyme)
ATC
R05CB13 — Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics
Dornaza alfa is a medication used for the treatment of cystic fibrosis. It is a recombinant enzyme that breaks down DNA in the thick mucus accumulated in the lungs, facilitating its clearance and improving respiratory function.

The medication is administered via inhalation, usually once daily, using a nebulizer. It is effective in reducing the frequency of respiratory infections and alleviating respiratory symptoms.

Side effects may include sore throat, hoarseness, skin rash, and, in rare cases, severe allergic reactions. Regular monitoring is essential to assess treatment effectiveness.

Consult your doctor to discuss the benefits and risks of treatment with Dornaza alfa. Follow the usage instructions to ensure therapy effectiveness.

General data about PULMOZYME 2500U / 2.5ml

Substance:
dornase alfa
Date of latest medicines list:
01-06-2026
Product code:
W61214001
Concentration:
2500U / 2.5ml
Pharmaceutical form:
solution for inhalation by nebuliser
Packing volume:
2,5 ml
Product type:
Original
Price:
549.37 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
ROCHE PHARMA AG - GERMANIA
Holder:
ROCHE ROMANIA S.R.L. - ROMANIA
Number:
6524/2014/01
Shelf life:
2 years

Pharmaceutical forms available for dornase alfa

Concentrations available for dornase alfa

  • 1mg/ml
  • 2500U/2.5ml

Compensation lists for PULMOZYME 2500U / 2.5ml Roche

NHP 6.4 (C2) - Cystic fibrosis

Price
549.37 RON
Copayment
549.37 RON
Patient
0.00 RON

NHP 9.1 (C2) - Spinal cord transplant

Price
549.37 RON
Copayment
549.37 RON
Patient
0.00 RON